



LEP BIOMEDICAL

ELIMINATING FIBROSIS IN GLAUCOMA DRAINAGE SURGERIES



BUSINESS SUMMARY:

LEP Biomedical have developed a flexible platform technology (HyaGuard™) that effectively delivers anti-inflammatory drugs to the eye following surgeries instead of traditional eye-drops. This simultaneously improves patient quality of life and reduces complications and repeat surgeries. LEP Biomedical is focused on the glaucoma post-op market due to its long-standing need for such a solution and its market size (>500k procedures performed per year)

TEAM:



Dr Alan Hibbitts
CEO/Founder/Inventor



Dr Ronan MacLoughlin
Non-Executive Director



Prof. Colm O'Brien
CMO / Co-Inventor

INDUSTRY: Ophthalmology/Pharma
DATE FOUNDED: 2023
COMPANY STAGE: Pre-Clinical
FUNDING: Enterprise Ireland [€100,000 CLN]

CONTACT

<https://www.lepbiomedical.com/>

Dr Alan Hibbitts
CEO/Founder/Inventor
Email: alanhibbitts@lepbiomedical.com

Dr Conor MacCormack
RCSI, Spin out Company Manager
Email: conormaccormack@rcsi.ie

MARKET OPPORTUNITY:

- 80 million people worldwide with glaucoma.
- \$10B+ USA & EU cost of glaucoma induced vision loss.
- 50-65% of “mild” patients deteriorate by 36 months of treatment.
- 500,000+ glaucoma drainage procedures annually.
- \$380 million lost due to surgical failure annually [USA].
- Year 1 Failure of 14-46% depending on surgery type.
- \$346M HyaGuard™ unit revenue SOM projected when fully scaled.
- \$50M EBITDA at M36 HyaGuard™ post-launch projected.


MARKET READINES

- Pre-clinical Validation.
- US + EU IP filings.
- CMC Strategy in place.
- Regulatory Strategy in place.
- End User Need Validated.

CUTTING EDGE TECHNOLOGY:

Product

- A biodegradable platform, HyaGuard™, offers controlled anti-inflammatory release, to reduce post-operative inflammation and scarring in glaucoma patients.
- A companion product for moderate-refractory drainage surgeries
- HyaGuard™ is positioned as a first mover in post-op care for glaucoma surgeries, with the potential to disrupt the current standard of care and improve patient outcomes.
- Key Features:
 - Easily inserted under the conjunctiva (<30 sec)
 - Biodegradable
 - Not externally visible
- For the patient: no drops required
- For the surgeon: simple and rapid insertion, value add to many surgeries
- For the healthcare provider: reduced failures, reoperations & rescues



INVESTMENT:

- Seeking Seed Round: €4.7M [3yr runway]
- Use of funds:
 - Regulatory: RFD / CTA / IND.
 - Clinical Trails: Pre-clinical -> First in Human.
 - Reimbursement.
 - IP filings.
 - GMP manufacture.

